February 1, 2017
Biomarin’s hemophilia drug nets PRIME status in Europe
BioMarin Pharmaceutical’s treatment for hemophilia has been accepted for PRIME (Priority Medicines) scheme from the European Medicines Agency (EMA).
Pharmaceuticals, Biotechnology and Life Sciences
Tag: PRIME